Understanding the European Medicines Agency's role requires clarity on one fundamental distinction: the EMA regulates medicinal products, not chemical substances as such. This distinction determines everything about where research peptides sit within — or, more precisely, outside — the European regulatory architecture.
This entry explains the EMA's centralised procedure, the national authorisation pathways that complement it, and precisely where research-use-only peptides fall in the regulatory gap between chemical substance regulation and pharmaceutical law.
The EMA: Role and Scope
The European Medicines Agency (EMA), based in Amsterdam, is an agency of the European Union responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the EU. It was established by Council Regulation (EEC) No 2309/93, subsequently replaced by Regulation (EC) No 726/2004, which remains the principal legal basis for the centralised procedure.
The EMA does not approve substances; it approves medicinal products — specific formulations of specific compounds, with defined indications, dosing, manufacturing standards, labelling requirements, and post-marketing surveillance obligations. A peptide such as semaglutide does not exist within the EMA framework as a loose compound; it exists as Ozempic® or Wegovy®, each with a specific EMA-approved Summary of Product Characteristics (SmPC).
The Centralised Procedure
The centralised procedure allows pharmaceutical companies to submit a single marketing authorisation application to the EMA for evaluation. If approved, the resulting marketing authorisation is valid in all 27 EU member states, plus Iceland, Liechtenstein, and Norway (under the EEA Agreement). This is the pathway used for most innovative medicines, including biologicals and biotech-derived products.
Application submission
The applicant (usually a pharmaceutical company) submits a full dossier to the EMA covering quality, safety, and efficacy data — the QSE triad that forms the basis of all medicines regulation.
Scientific evaluation by CHMP
The Committee for Medicinal Products for Human Use (CHMP), composed of experts from member state NCAs, conducts the scientific review over a 210-day active clock period.
CHMP opinion
The CHMP issues a positive or negative opinion. A positive opinion recommends granting the marketing authorisation and is the basis for the European Commission's formal decision.
European Commission decision
The Commission grants the marketing authorisation, which is then valid across all EU/EEA member states. The authorisation holder must maintain the product in line with the approved SmPC and report adverse events through pharmacovigilance systems.
National Procedures: MRP and DCP
Not all medicines use the centralised procedure. For products that do not fall within the mandatory centralised scope, two decentralised mechanisms exist:
- Mutual Recognition Procedure (MRP): A product first authorised in one member state (the Reference Member State) is then mutually recognised by other member states. NCAs of concerned member states assess and accept the reference authorisation.
- Decentralised Procedure (DCP): An application submitted simultaneously to multiple member states, with one acting as Reference Member State to coordinate the scientific review.
Both procedures result in national marketing authorisations issued by each individual NCA, not a single pan-European authorisation — though the underlying scientific assessment is shared.
Where Research-Use-Only Peptides Fall
Research-use-only (RUO) peptides — synthesised peptides sold without a marketing authorisation, labelled for in vitro or preclinical research purposes — are entirely outside the EMA framework. The EMA has no mandate over them, issues no guidance on their quality, and has no surveillance mechanism for their adverse effects.
This regulatory gap has several practical consequences:
- No mandatory quality control: there is no requirement for GMP manufacturing, sterility testing, or identity verification before sale
- No pharmacovigilance: adverse events associated with RUO peptides used outside research settings are not systematically collected or reported to any EU body
- No labelling standards: the "research use only" designation itself carries no standardised meaning across member states
- National NCA jurisdiction: the import, possession, and use of RUO peptides is governed by national law in each member state — which varies considerably in how strictly it interprets the boundary between research chemicals and medicinal products
The EMA's Relevant Positions
The EMA does not issue specific guidance on RUO peptides per se, but its positions on several adjacent matters are directly relevant. The CHMP's reflection paper on GLP-1 receptor agonists, published guidance on biosimilars, and the EMA's ongoing work on the clinical development of peptide therapeutics all assume a framework of authorised products with documented quality chains — a framework that RUO supply chains structurally cannot replicate.
The EMA's PROTECT programme and SCOPE joint action have documented the problem of falsified medicines — including products imitating EMA-authorised peptide drugs — entering the informal supply chain. These are not the same as RUO research peptides, but the two categories overlap in practice when EMA-authorised compounds (semaglutide, tirzepatide) are also sourced as RUO research chemicals from non-pharmaceutical channels.
The Practical Conclusion for Researchers
The EMA framework provides strong quality and safety assurances — but only for authorised medicinal products obtained through authorised supply chains. Once a researcher sources a compound outside that framework, the entire quality assurance architecture falls away. Independent analytical verification (HPLC + LC-MS from an independent laboratory) becomes the only available proxy for the quality control the EMA system would otherwise provide. It is a pale substitute, but it is the only one that exists.